biostudies-literatureUnknown17Yang WG<h4>Background</h4>Artemisinin (ART) is a safe and effective antimalarial drug. In recent years, antimalarial drugs have demonstrated a good therapeutic efficacy in IgA nephropathy, suggesting that this may become a new treatment option.<h4>Purpose</h4>We aimed to evaluate the effect and mechanism of artemisinin in IgA nephropathy.<h4>Methods</h4>In this study, CMap database was used to predict the artemisinin therapeutic effect for IgA nephropathy. A network pharmacology approach was applied to explore the unknown mechanism of artemisinin in IgA nephropathy. We used molecular docking to predict the binding affinity of artemisinin with the targets. A mouse model of IgA nephropathy was established to investigate the therapeutic effect of artemisinin on IgA nephropathy. In vitro, the cell coDrug design, development and therapy1679-1697https://www.ebi.ac.uk/biostudies/studies/S-EPMC10257916biostudies-literatureExploration of Artemisinin Against IgA Nephropathy via AKT/Nrf2 Pathway by Bioinformatics and Experimental Validation.PMC10257916Yang WGHe WJSun ALiu LLLiu NZhu RfalseExploration of Artemisinin Against IgA Nephropathy via AKT/Nrf2 Pathway by Bioinformatics and Experimental Validation.<h4>Background</h4>Artemisinin (ART) is a safe and effective antimalarial drug. In recent years, antimalarial drugs have demonstrated a good therapeutic efficacy in IgA nephropathy, suggesting that this may become a new treatment option.<h4>Purpose</h4>We aimed to evaluate the effect and mechanism of artemisinin in IgA nephropathy.<h4>Methods</h4>In this study, CMap database was used to predict the artemisinin therapeutic effect for IgA nephropathy. A network pharmacology approach was applied to explore the unknown mechanism of artemisinin in IgA nephropathy. We used molecular docking to predict the binding affinity of artemisinin with the targets. A mouse model of IgA nephropathy was established to investigate the therapeutic effect of artemisinin on IgA nephropathy. In vitro, the cell co2023-01-01T00:00:00Z20232025-04-04T10:21:21.932Z2025-02-19T02:37:56.818ZS-EPMC102579163730941510.2147/DDDT.S403422